What is the recommended prescription for an adult with functional dyspepsia without alarm features?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prescription for Functional Dyspepsia

For adults with functional dyspepsia without alarm features, first test for Helicobacter pylori using a non-invasive breath or stool test; if positive, prescribe eradication therapy, and if negative or symptoms persist after eradication, prescribe a proton pump inhibitor (PPI) at standard dose once daily for 4-8 weeks. 1, 2

Initial Diagnostic Approach

  • Test all patients for H. pylori using a 13C-urea breath test or stool antigen assay as these are the preferred non-invasive methods with high accuracy. 1, 2

  • If H. pylori is positive, provide eradication therapy immediately using triple therapy (a PPI with clarithromycin and amoxicillin) because this leads to symptom improvement in approximately 1 in 15 patients and may reduce future gastric cancer risk. 1, 2, 3

  • After successful eradication, reassess symptoms before starting acid suppression, as some patients will achieve complete resolution. 2

First-Line Pharmacologic Treatment

Prescribe a standard-dose PPI once daily for 4-8 weeks for patients who are H. pylori negative or whose symptoms persist after successful eradication. 1, 2

  • PPIs are superior to H2-receptor antagonists, antacids, and placebo for functional dyspepsia with strong evidence quality. 2, 4

  • The PPI trial benefits both epigastric pain syndrome (ulcer-like dyspepsia) and postprandial distress syndrome. 2

  • Examples include omeprazole 20 mg, lansoprazole 30 mg, or esomeprazole 40 mg once daily. 3, 4

Second-Line Treatment for Persistent Dysmotility Symptoms

If symptoms of postprandial fullness, early satiety, bloating, or upper abdominal discomfort persist after the PPI trial:

  • Add itopride as the first-line prokinetic agent because it has an excellent safety profile with adverse events occurring in only 1.5-3% of patients, no cardiac toxicity, and no QT prolongation. 2

  • Itopride can be used as add-on therapy to a PPI when acid suppression alone is insufficient. 2

  • Alternative prokinetics (cinitapride, mosapride) provide only modest benefit with lower quality evidence. 2

Second-Line Treatment for Persistent Pain or Refractory Symptoms

For patients who fail PPI therapy and have predominant epigastric pain or refractory symptoms:

  • Prescribe amitriptyline starting at 10 mg nightly and titrate slowly to 30-50 mg nightly as tolerated. 2, 5, 4

  • Tricyclic antidepressants are the most evidence-based option for refractory functional dyspepsia with moderate-quality evidence and response rates of 64-70%. 2, 6, 4

  • For patients with mixed pain and dysmotility symptoms, consider adding levosulpiride 25 mg three times daily to amitriptyline, though counsel patients about additive drowsiness and possible hyperprolactinemia. 2

Critical Clinical Caveats

  • Do not perform routine gastric emptying testing or 24-hour pH monitoring in patients with typical functional dyspepsia symptoms, as these add little diagnostic value. 1

  • Avoid repetitive or extensive diagnostic testing in the absence of alarm features, as this yields low benefit and is not cost-effective compared to empirical management. 2, 7

  • Establish an empathic doctor-patient relationship and explain that functional dyspepsia is a disorder of gut-brain interaction affected by diet, stress, and emotional responses, as this may reduce healthcare utilization and improve quality of life. 1

  • If symptoms respond to initial therapy, stop treatment after 4-8 weeks; if symptoms recur, another course of the same treatment is justified. 8

When to Consider Endoscopy or Referral

  • Endoscopy is not mandatory in young patients who fail empirical therapy without alarm features, as the diagnostic yield is very low. 1

  • Refer to gastroenterology when diagnostic doubt exists, symptoms are severe or refractory to first-line treatments, or the patient requests specialist opinion. 1, 5

  • For patients ≥55 years with treatment-resistant dyspepsia or those with alarm features (weight loss, dysphagia, vomiting, bleeding, family history of gastric cancer), urgent endoscopy is warranted. 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Functional Dyspepsia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of New-Onset Dyspepsia in Elderly Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

ACG and CAG Clinical Guideline: Management of Dyspepsia.

The American journal of gastroenterology, 2017

Guideline

Treatment for Functional Dyspepsia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Guidelines for the management of dyspepsia.

The American journal of gastroenterology, 2005

Related Questions

What are the initial laboratory evaluations for patients presenting with functional dyspepsia?
What is the recommended follow-up approach for patients with functional dyspepsia (FD) after initiating treatment?
What is the initial approach to managing a patient with 3 months of dyspepsia?
What's the next best treatment step for a 31-year-old male with chronic epigastric pain (abdominal pain above the stomach), worsened by eating, with occasional nausea and diarrhea, whose symptoms have not improved with proton pump inhibitors (PPIs) and has a normal endoscopy and biopsy result, and is currently taking loperamide (anti-diarrheal medication)?
A patient presents with upper abdominal pain in the epigastric area after eating, what could it be and what is the treatment?
Do thiocolchicoside and tolperisone interact, and is it safe to use them together?
Should regional nodal irradiation be given in an adult with clinical T3 N0 HER2‑positive breast cancer who achieved a pathologic complete response after neoadjuvant trastuzumab ± pertuzumab with taxane chemotherapy and has undergone breast‑conserving surgery or mastectomy with clear margins and no prior chest irradiation?
How should IgA nephropathy be diagnosed and managed, including blood pressure targets, proteinuria goals, and the use of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), corticosteroids, cyclophosphamide, or mycophenolate mofetil?
In a child with dysentery and an abnormal coagulation profile, should fresh‑frozen plasma be given?
How should I manage a patient presenting with odynophagia and minimal thickening of the epiglottis, glottis, and arytenoids?
In acute decompensated heart failure with systolic blood pressure <90 mmHg, what pharmacologic agents can be used to restore perfusion pressure and improve cardiac contractility?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.